This article was downloaded by: [Umeå University Library] On: 10 October 2014, At: 02:56 Publisher: Taylor & Francis Informa Ltd Registered in England and Wales Registered Number: 1072954 Registered office: Mortimer House, 37-41 Mortimer Street, London W1T 3JH, UK



Phosphorus, Sulfur, and Silicon and the Related Elements

Publication details, including instructions for authors and subscription information: <u>http://www.tandfonline.com/loi/gpss20</u>

Synthesis, Characterization, and Antiproliferative Activity of 2-(2-Bromo-5-methoxyphenyl)-6-aryl-1,3thiazolo[3,2b][1,2,4]triazoles

B. Narayana^a, K. K. Vijaya Raj^a & B. K. Sarojini^b ^a Department of Post-Graduate Studies and Research in Chemistry, Mangalore University, Mangalagangotri, India

^b Department of Chemistry, P. A. College of Engineering, Nadupadavu, Mangalore, India Published online: 03 Feb 2010.

To cite this article: B. Narayana , K. K. Vijaya Raj & B. K. Sarojini (2010) Synthesis, Characterization, and Antiproliferative Activity of 2-(2-Bromo-5-methoxyphenyl)-6-aryl-1,3-thiazolo[3,2b] [1,2,4]triazoles, Phosphorus, Sulfur, and Silicon and the Related Elements, 185:2, 306-312

To link to this article: <u>http://dx.doi.org/10.1080/10426500902775646</u>

PLEASE SCROLL DOWN FOR ARTICLE

Taylor & Francis makes every effort to ensure the accuracy of all the information (the "Content") contained in the publications on our platform. However, Taylor & Francis, our agents, and our licensors make no representations or warranties whatsoever as to the accuracy, completeness, or suitability for any purpose of the Content. Any opinions and views expressed in this publication are the opinions and views of the authors, and are not the views of or endorsed by Taylor & Francis. The accuracy of the Content should not be relied upon and should be independently verified with primary sources of information. Taylor and Francis shall not be liable for any losses, actions, claims, proceedings, demands, costs, expenses, damages, and other liabilities whatsoever or howsoever caused arising directly or indirectly in connection with, in relation to or arising out of the use of the Content.

This article may be used for research, teaching, and private study purposes. Any substantial or systematic reproduction, redistribution, reselling, loan, sub-licensing, systematic supply, or distribution in any form to anyone is expressly forbidden. Terms &

Conditions of access and use can be found at <u>http://www.tandfonline.com/page/terms-and-conditions</u>



Phosphorus, Sulfur, and Silicon, 185:306–312, 2010 Copyright © Taylor & Francis Group, LLC ISSN: 1042-6507 print / 1563-5325 online DOI: 10.1080/10426500902775646

SYNTHESIS, CHARACTERIZATION, AND ANTIPROLIFERATIVE ACTIVITY OF 2-(2-BROMO-5-METHOXYPHENYL)-6-ARYL-1,3-THIAZOLO[3,2*b*] [1,2,4]TRIAZOLES

B. Narayana,¹ K. K. Vijaya Raj,¹ and B. K. Sarojini²

¹Department of Post-Graduate Studies and Research in Chemistry, Mangalore University, Mangalagangotri, India ²Department of Chemistry, P. A. College of Engineering, Nadupadavu, Mangalore, India

Eight new 2-(2-bromo-5-methoxyphenyl)-6-aryl-1,3-thiazolo[3,2-b][1,2,4]triazoles were synthesized by treating 5-(2-bromo-5-methoxyphenyl)-4H-1,2,4-triazole-3-thiol with phenacyl bromides. The new products were characterized by spectroscopic and analytical methods. Five of the new compounds were evaluated for their antiproliferative activity. 2-(2-Bromo-5-methoxyphenyl)-6-(3,4-dihydroxyphenyl)-1,3-thiazolo[3,2-b] [1,2,4]triazole exhibited promising activity.

Supplemental materials are available for this article. Go to the publisher's online edition of Phosphorus, Sulfur, and Silicon and the Related Elements to view the free supplemental file.

Keywords Antiproliferative activities; *N*-bridged heterocycles; characterization; synthesis; thiazolotriazoles

INTRODUCTION

The synthesis of heterocyclic systems containing bridgehead nitrogen atom gained considerable attention due to their wide range of biological activities. Many of the thiazolo[3,2-b]-1,2,4-triazoles have been reported as anthelmintics,¹ bactericides,² medicinal fungicides,³ cardiotonics, and bronchodilators.⁴ In continuation of our research work on thiazolotriazoles⁵ and compounds containing a 2-bromo-5-methoxyphenyl moiety,⁶ we aimed to synthesize new 2-(2-bromo-5-methoxyphenyl)-6-aryl-1,3-thiazolo[3,2*b*][1,2,4]triazoles and investigate their antiproliferative activity.

Received 20 August 2008; accepted 26 January 2009.

The present affiliation for K. K. Vijaya Raj is GE India Technology Center Pvt Ltd, Bangalore, India.

The authors are thankful to The Head, SAIF, CDRI, Lucknow, and The Director, SAIF, Punjab University for spectral analysis. Authors are also thankful to Dr. V. L. Narayanan, National Institute of Health (NIH), Bethesda, MD, USA, for arranging the antiproliferative activity screening studies reported in this article.

Address correspondence to B. Narayana, Department of Post-Graduate Studies and Research in Chemistry, Mangalore University, Mangalagangotri, 574 199, India. E-mail: nbadiadka@yahoo.co.uk

The reaction of α -haloketones (2) with 2-substituted 5-mercapto-1,2,4-triazoles (1) is expected to result in the formation of either 2,5-disubstituted thiazolo[3,2-b]-1,2,4triazoles (3) or 3,5-disubstituted thiazolo[2,3-c]-1,2,4-triazoles (4), or both, $^{7-10}$ as given in Scheme 1. Jag Mohan¹¹ reported that the reaction of 3-(4-tolyl)-5-mercapto-1,2,4-triazole with 4-substituted phenacyl bromides in dry methanol gives thiazolo[3,2-b][1,2,4]triazoles in one step and not the isomeric thiazolo[2,3-c]-1,2,4-triazoles. This was also supported by the synthesis of thiazolo[3,2-b]-1,2,4-triazoles reported by Narayana et al.¹² Reaction of mercaptotriazole (5) (R=H) with bromoketones (6) in ethanol followed by cyclization in polyphosphoric acid yielded the thiazolo[3,2-b]-1,2,4-triazoles (7) and not the isomeric thiazolo[2,3-c]-1,2,4-triazoles (8), which was established by comparison with an authentic sample of 8 ($R^1 = 4$ -MeC₆H₄) obtained by cyclization of 2-(4-bromobenzoyl)hydrazino-4-(4-tolyl)thiazole-hydrobromide (9) (Scheme 2).¹¹ The melting point, IR spectrum, and thinlayer chromatographic behavior were used to identify this product. The reaction of 5 (R=H) with 6 in methanol led, however, directly to the cyclized products 7 (Scheme 3). In view of these observations, we decided to synthesize further new 2-(2-bromo-5-methoxyphenyl)-6-aryl-1,3-thiazolo[3,2-b][1,2,4]triazoles by treating 5-(2-bromo-5-methoxyphenyl)-4H-1,2,4-triazole-3-thiol with phenacyl bromides in methanol. With the help of a single crystal X-ray study,¹³ we have established that the cyclization resulted in the formation of 2-(2-bromo-5-methoxyphenyl)-6-aryl-1,3-thiazolo[3,2-b][1,2,4]triazoles only, and not the isomeric thiazolo[2,3-c][1,2,4]triazoles.



Scheme 1

RESULTS AND DISCUSSION

Chemistry

The compound 5-(2-bromo-5-methoxyphenyl)-4*H*-1,2,4-triazole-3-thiol (**10**) was synthesized by the reaction of 2-bromo-5-methoxybenzhydrazide with potassium thiocyanate and concentrated aqueous hydrogen chloride, followed by cyclization of the resulting 1-(2-bromo-5-methoxybenzoyl)thiosemicarbazide with sodium hydroxide.⁵ The





structure of the starting compound (**10**) was confirmed by recording ¹H NMR in DMSO-d₆ and mass spectra. A singlet at $\delta = 3.82$ was due to three protons of the OCH₃ group. A doublet of doublet observed at $\delta = 7.07$ (J = 3.1, 8.8 Hz), a doublet at $\delta = 7.23$ (J = 2.9 Hz), and another doublet at $\delta = 7.68$ (J = 8.8 Hz) accounts for the three aromatic protons. The SH and NH protons appeared as two downfield singlets at $\delta = 13.66$ and $\delta = 13.75$, respectively. The mass spectrum displayed the molecular ion peaks at m/z = 286 (80% ⁷⁹Br-**10**) and 288 (90% ⁸¹Br-**10**). Further fragment peaks appeared at m/z = 254 (10%, M⁺—SH), m/z = 176 (45%, phenyl mercaptotriazole radical cation), and m/z = 136 (70%, MeOC₆H₄CNH⁺).

The 1,2,4-triazole (10) was then refluxed in ethanol with the phenacyl bromides (11a-h) to get 2-(2-bromo-5-methoxyphenyl)-6-aryl-1,3-thiazolo[3,2-*b*][1,2,4]triazoles (12a-h) (Scheme 4).



Scheme 3





The isomeric thiazolo[2,3-c][1,2,4]triazoles were not formed in this reaction. This was confirmed by the synthesis of 3-(2-bromo-5-methoxyphenyl)-5-phenyl-1,3-thiazolo[2,3-c]-1,2,4-triazole (**13**) by the cyclization of 2-bromo-5-methoxy-N'-[4-phenyl-1,3-thiazol-2-yl]benzohydrazide (**9**) (Scheme 5).



Scheme 5

The melting point, IR spectrum, and thin-layer chromatographic behavior were used to differentiate this product from 2-(2-bromo-5-methoxyphenyl)-6-phenyl-1,3-thiazolo[3,2-*b*]-1,2,4-triazole (**12a**). A single crystal X-ray study¹³ of (**12a**), formed according to Scheme 4, unequivocally revealed its structure. In a few cases, acyclic products were isolated and identified by IR and mass spectra. These acyclic compounds were then cyclized by refluxing in methanol.

The new 2-(2-bromo-5-methoxyphenyl)-6-aryl-1,3-thiazolo[3,2-b]1,2,4-triazoles (**12a–h**) were also well characterized by analytical and spectroscopic analyses to prove their assigned structure. Characterization data are given in Table I.

4
01
ล
er
Ą.
Ĕ
ŏ
õ
56
2
Ö
at
$\overline{\mathbf{x}}$
F.
OĽ
5
<u>,</u>
Ξ,
SLS
Λe
Ξ.
\Box
ça
Ĕ
D
2
Ģ,
g
ld€
oa
H
wn
Jown]

ψ	
Ξ	
Suy	
bh(
Ļ.	
Ę.	
eny	
hh	
X	
thc	
me	
5-	
ģ	
uo.	
Ę.	
ů,	
3	
n	
i,	
Ţ	
128	
Ξ.	
les	
IZO	
Ξ	
£	
5,	
Ĭ	
2-1	
Ľ.	
90	
azc	
thi	
ψ	
Ξ	
ary	
5	
÷	
ŝ	
bhé	
xy	
ho	
net	
5-1	
6	
_	
mo	
-brom	
-(2-brom	
2-(2-brom	
the 2-(2-brom	
of the 2-(2-brom	(13)
a of the 2-(2-brom	ile (13)
data of the 2-(2-brom	azole (13)
al data of the 2-(2-brom	triazole (13)
ental data of the 2-(2-brom	.,4]triazole (13)
imental data of the 2-(2-brom	1,2,4]triazole (13)
perimental data of the 2-(2-brom	b][1,2,4]triazole (13)
Experimental data of the 2-(2-brom	,2-b][1,2,4]triazole (13)
Experimental data of the 2-(2-brom	o[3,2-b][1,2,4]triazole (13)
e I Experimental data of the 2-(2-brom	olo[3,2-b][1,2,4]triazole (13)
able I Experimental data of the 2-(2-brom	iazolo[3,2- <i>b</i>][1,2,4]triazole (13)

						Elemental :	analvsis (%) Four	d (Caled.)
		Molecular	Meltino	Yield		Implication	mo t (a) and thum	
Nr.	Ar	formula	point°C	%	Color	C	Н	z
12a	Phenyl	C ₁₇ H ₁₂ BrN ₃ OS	208-210	48	Cream	52.78 (52.86)	3.05 (3.13)	10.80 (10.88)
12b	3-Chloro-pyridyl	C ₁₆ H ₁₀ BrCIN ₄ OS	226–228	46	Dark yellow	45.49 (45.57)	2.31 (2.39)	13.21 (13.29)
12c	3,4-Dihy-droxyphenyl	$C_{17}H_{12}BrN_3O_3S$	210-212	68	Light yellow	48.74 (48.82)	2.81 (2.89)	9.97 (10.05)
12d	3-Carbamo-yl-4-hy-droxyphenyl	$C_{18}H_{13}BrN_4O_3S$	245-248	55	Cream	48.47 (48.55)	2.86 (2.94)	12.50 (12.58)
12e	2-Oxo-chrom-en-3-yl	$C_{20}H_{12}BrN_3O_3S$	220-222	51	Off white	52.80 (52.88)	2.58 (2.66)	9.17 (9.25)
12f	6-Bromo-2-oxochrom-en-3-yl	$C_{20}H_{11}Br_2N_3O_3S$	196 - 198	88	Yellow	44.97 (45.05)	2.00 (2.08)	7.80 (7.88)
12g	4-Chloro-phenyl	C ₁₇ H ₁₁ BrCIN ₃ OS	238-241	59	Yellow	48.45 (48.53)	2.58 (2.64)	9.91 (9.99)
12h	4-Methoxy-phenyl	$C_{18}H_{14}BrN_3O_2S$	168 - 170	78	Yellow	51.87 (51.93)	3.31 (3.39)	10.01 (10.09)
13	Phenyl	C ₁₇ H ₁₂ BrN ₃ OS	162 - 164	58	White	52.88 (52.86)	3.15 (3.13)	10.82 (10.88)

Antiproliferative Activity

Five of the new compounds (**12b–d**, **12g**, and **12h**) were screened for their antiproliferative activity at The National Institutes of Health (NIH), Bethesda, Maryland, USA, under the Drug Discovery Programme of NCI as per the procedure suggested by Boyd and Paull¹⁴ in a primary, three-cell, line-one dose antitumor assay against NCI-H (lung), MCF-7 (breast), and SF 268 (CNS). Further experimental details and Table II-S are available in the Supplemental Materials online.

CONCLUSION

Nine new 2-(2-bromo-5-methoxyphenyl)-6-aryl-1,3-thiazolo[3,2-*b*][1,2,4]triazoles were synthesized and evaluated for their antiproliferative activity. The compound 2-(2-bromo-5-methoxyphenyl)-6-(3,4-dihydroxyphenyl)-1,3-thiazolo[3,2-*b*][1,2,4]triazole (**12c**) emerged as the most active one and can be recommended for further studies. As the selection of the compound was done by NCI, the prediction of structure–activity relationship is difficult to determine at this point of time.

EXPERIMENTAL

Melting points were taken in open capillary tubes and are uncorrected. The purity of the compounds was confirmed by thin layer chromatography using Merck silica gel 60 F_{254} coated aluminum plates. IR spectra were recorded on a Shimadzu-FTIR spectrometer in KBr (ν in cm⁻¹). ¹H NMR spectra were recorded in CDCl₃ and in DMSO-d₆ on a Varian (300 MHz) spectrometer using TMS as internal standard, and ¹³C NMR spectra were recorded in CDCl₃ and in DMSO-d₆ on a Varian (75 MHz) spectrometer. FABMS spectra were recorded on a JEOL SX 102/DA-6000 mass spectrometer (6 kV, 10mA) using argon/xenon as the FAB gas.

5-(2-Bromo-5-methoxyphenyl)-4H-1,2,4-triazole-3-thiol (10)

1-(2-Bromo-5-methoxybenzoyl)thiosemicarbazide (50 g, 0.164 mol) was refluxed with 500 mL of 5% sodium hydroxide solution for 4 h and was cooled and filtered. The clear solution was acidified with conc. HCl to pH 5–6. The solid obtained was filtered and recrystallized (MeOH) to give white crystals; yield, 42 g (89%), mp >250°C

2-(2-Bromo-5-methoxyphenyl)-6-aryl-1,3-thiazolo[3,2-*b*][1,2,4]triazoles (12a-h)

5-(2-Bromo-5-methoxyphenyl)-4H-1,2,4-triazole-3-thiol (10) (0.01 mol) and the appropriate phenacyl bromide (11) (0.01 mol) were refluxed in ethanol for 4 h. The progress of the reaction was monitored by TLC. After the completion of the reaction, the reaction mixture was cooled and the precipitated solid was filtered off. The solid was recrystallized from MeOH/DMF. The compounds were obtained in 40–88% yield (see Table I).

Spectroscopic Data

2-(2-Bromo-5-methoxyphenyl)-6-phenyl-1,3-thiazolo[3,2-*b***][1,2,4]triazole (12a)¹³. IR: 3118, 3070 (CH), 1560 (C=N), 734 (C-Br); ¹H NMR (DMSO-d₆): \delta 3.8 (s, 3H, OCH₃), 7.03 (dd, J = 3.3, 8.7 Hz, 1H, ArH), 7.44 (s, 1H, ArH), 7.55 (m, 3H, ArH), 7.67 (d, J = 8.7 Hz, 1H, ArH), 8.01 (s, 1H, ArH), 8.27 (d, J = 7.8 Hz, 1H, NH); ¹³C NMR (DMSO-d₆): \delta 55.62, 111.14, 111.47, 116.96, 117.31, 126.27, 127.57, 129.00, 129.69, 131.52, 132.57, 134.66, 158.43; DEPT: 55.64, 111.16, 116.98, 117.34, 126.29, 129.04, 129.73, 134.68. FABMS: m/z 388 (95%, M⁺ + 1), 387 (20%, M⁺ + 1), 386 (100%, M⁺ + 1), 307 (12%, M⁺—Br), 136 (40%, MeOC₆H₄CNH⁺).**

2-(2-Bromo-5-methoxyphenyl)-6-(3,4-dihydroxyphenyl)-1,3-thiazolo[3,2*b*][**1,2,4**]triazole (12c). IR: 3400 (OH), 3109 (CH), 1562 (C=N), 734 (C-Br); ¹H NMR (CDCl₃): δ 3.85 (s, 3H, OCH₃), 6.87 (dd, J = 2.9, 8.7 Hz, 1H, ArH), 7.02 (s, 2H, ArH), 7.26 (s, 5H, 2-OH + H₂O), 7.45 (d, J = 3.0 Hz, 1H, ArH), 7.61 (d, J = 8.7 Hz, 2H, ArH), 7.82 (s, 1H, ArH). FABMS: *m/z* 420 (75%, M⁺ + 1), 419 (45%, M⁺ + 1), 418 (73%, M⁺ + 1), 136 (98%, MeOC₆H₄CNH⁺).

2-(2-Bromo-5-methoxyphenyl)-6-(3-carbamoyl-4-hydroxyphenyl)-1,3-thiazolo-[3,2-b][1,2,4]triazole (12d). IR: 3411 (OH), 3336 (NH₂), 1595 (C=N), 821 (C-Br); FABMS: m/z 447 (80%, M⁺ + 1) 446 (60%, M⁺), 445 (70%, M⁺ + 1), 136 (90%, MeOC₆H₄CNH⁺).

2-(2-Bromo-5-methoxyphenyl)-6-(4-methoxyphenyl)-1,3-thiazolo[3,2-*b***] [1,2,4]-triazole (12h).** IR: 3114, 2898 (CH), 1560 (C=N), 1022, 812 (C-Br); ¹H NMR (CDCl₃): δ 3.83 (s, 3H, OCH₃), 3.85 (s, 3H, OCH₃), 6.86 (dd, J = 3.4, 8.8 Hz, 1H, ArH), 6.99 (s, 1H, ArH), 7.00 (dd, J = 1.8, 6.9 Hz, 2H, ArH), 7.49 (d, J = 3.0 Hz, 1H, ArH), 7.60 (d, J = 8.8 Hz, 1H, ArH), 8.11 (dd, J = 2.04, 8.7 Hz, 2H, ArH); FABMS: *m/z* 418 (100%, M⁺ + 1), 417 (60%, M⁺ + 1), 416 (98%, M⁺ + 1), 136 (60%, MeOC₆H₄CNH⁺).

3-(2-Bromo-5-methoxyphenyl)-5-phenyl-1,3-thiazolo[2,3-*c***]**[1,2,4]triazole (13). IR: 3114, 2898 (CH), 1560 (C=N), 1022, 812 (C-Br); ¹H NMR (CDCl₃): δ 3.85 (s, 3H, OCH₃), 6.99 (dd, J = 3.6, 9.0 Hz, 1H, ArH), 7.37–7.48 (m, 4H, ArH), 7.63 (d, J = 8.7 Hz, 1H, ArH), 7.79 (s, 1H, ArH), 8.0 (d J = 7.2 Hz, 2H, ArH).

REFERENCES

- 1. I. Simiti and A. Marie, Rev. Roum. Chim., 27, 273 (1982).
- 2. J. Mohan, G. S. R. Anjaneyulu, P. Verma, and K. V. S. Yamini, Ind. J. Chem., 29B, 88 (1990).
- 3. B. S. Holla, K. N. Poojary, B. Kalluraya, and P. V. Gowda, Il Farmaco, 51 793 (1996).
- 4. D. Takiguchi, T. Sato, and S. Nomura, JP 61286387 (1985); Chem. Abstr., 106, 138456 (1987).
- 5. K. K. Vijaya Raj and B. Narayana, Phosphorus, Sulfur, and Silicon, 181, 1971 (2006).
- K. K. Vijaya Raj, B. Narayana, B. V. Ashalatha, and N. Suchetha Kumari, *Eur. J. Med. Chem.*, 41, 425 (2007).
- 7. K. Pilgram and G. E. Pollard, J. Heterocycl. Chem., 13, 1225 (1976).
- 8. R. K. Gupta, M. L. Sachdeva, and H. K. Pujari, Ind. J. Chem., 15B, 1143 (1977).
- 9. K. K. Jain and R. N. Handa, Ind. J. Chem., 21B, 732 (1982).
- 10. G. Ramachandriah and K. K. Kondal Reddy, Ind. J. Chem., 24B, 808 (1985).
- 11. K. Jag Mohan, Chim. Acta Turc., 16, 91 (1988); Chim. Abstr., 111, 232685 (1986).
- 12. S. Narayana, R. N. Handa, and H. K. Pujari, Ind. J. Chem., 24B, 12 (1985).
- 13. H. S. Yathirajan, K. K. Vijaya Raj, B. Narayana, B. K. Sarojini, and M. Bolte, *Acta Crystallogr.*, **E62**, 04444 (2006).
- 14. M. R. Boyd and K. D. Paull, Drug. Dev. Res., 34, 91 (1995).